Conference Coverage
Advertisement
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
US veterans who were exposed to Agent Orange have an increased risk of myeloproliferative neoplasms.
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Patients admitted for atrial fibrillation who have myeloproliferative neoplasms have an increased risk of bleeding.
Extending colorectal cancer screening to older populations using stool testing results in more life years gained.
People with a history of skin cancer lack sufficient knowledge on photoprotection, study finds.
Ticagrelor monotherapy is linked with similar rates of recurrent coronary revascularization compared with standard therapy.
Dr. George D. Dangas, about a study he led which analyzed the predictive value of the thrombotic risk criteria.
Dr. Tanvir K. Bajwa talks about the FX TAVR system, designed to improve ease of use in coronary access.
Pulmonary embolism patients treated with mechanical thrombectomy have improved outcomes and quality of life.
Marijuana users incur more than three times the risk of developing peripheral artery disease.
The novel Supira 10F system is a safe and effective percutaneous ventricular assist device for high-risk PCI.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726